ALK and non-small cell lung carcinoma: The combination regimen produced longer OS and PFS than bevacizumab plus chemotherapy alone in the intent-to-treat population7,8; in addition, prolonged PFS was reported in the subgroup of patients with EGFR-mutant or ALK-positive NSCLC (median PFS = 9.7 versus 6.1 mo, HR = 0.59, 95% CI: 0.37–0.94).7